VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding

Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors

(2020) Vid Leko et al.   CANCER CELL

All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy

(2020) Evripidis Lanitis et al.   CURRENT OPINION IN BIOTECHNOLOGY

Antitumor effects of CAR T cells redirected to the EDB splice variant of fibronectin

(2020) Jessica Wagner et al.   Cancer Immunology Research

T cell engineered with a novel nanobody‐based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy

(2019) Fatemeh Hajari Taheri et al.   IUBMB LIFE

CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response

(2019) Nicholas F. Kuhn et al.   CANCER CELL

Direct measurements of VEGF:VEGFR2 binding affinities reveal the coupling between ligand binding and receptor dimerization

(2019) Christopher King et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The tumor vasculature an attractive CAR T cell target in solid tumors

(2019) Parvin Akbari et al.   ANGIOGENESIS

Consensus guidelines for the use and interpretation of angiogenesis assays

(2018) Patrycja Nowak-Sliwinska et al.   ANGIOGENESIS

VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells

(2018) Sergey V. Kulemzin et al.   Oncotarget

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

(2018) Paris Kosti et al.   Frontiers in Immunology

Tumor Antigen Escape from CAR T-cell Therapy

(2018) Robbie G. Majzner et al.   Cancer Discovery

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

(2017) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t Forget the Fuel

(2017) Melita Irving et al.   Frontiers in Immunology

Exploring Novel Methods for Modulating Tumor Blood Vessels in Cancer Treatment

(2016) Ping-Pui Wong et al.   CURRENT BIOLOGY

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab

(2016) G. A. Rufener et al.   Cancer Immunology Research

Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research

(2016) Kanako Inoo et al.   Molecular Therapy-Oncolytics

Targeting the tumor vasculature to enhance T cell activity

(2015) Evripidis Lanitis et al.   CURRENT OPINION IN IMMUNOLOGY

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

(2014) P. S. Adusumilli et al.   Science Translational Medicine

T Cells Bearing a Chimeric Antigen Receptor against Prostate-Specific Membrane Antigen Mediate Vascular Disruption and Result in Tumor Regression

(2014) S. P. Santoro et al.   Cancer Immunology Research

Simultaneous Targeting of Tumor Antigens and the Tumor Vasculature Using T Lymphocyte Transfer Synergize to Induce Regression of Established Tumors in Mice

(2013) D. Chinnasamy et al.   CANCER RESEARCH

Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency

(2013) W Wang et al.   GENE THERAPY

Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery

(2013) Xinping Fu et al.   INTERNATIONAL JOURNAL OF CANCER

Mouse Tumor Vasculature Expresses NKG2D Ligands and Can Be Targeted by Chimeric NKG2D-Modified T Cells

(2013) T. Zhang et al.   JOURNAL OF IMMUNOLOGY

Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy

(2012) N Kanagawa et al.   CANCER GENE THERAPY

Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice

(2012) D. Chinnasamy et al.   CLINICAL CANCER RESEARCH

Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization

(2011) M. S. Brozzo et al.   BLOOD

Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor

(2011) Evripidis Lanitis et al.   MOLECULAR THERAPY

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

The Structural Basis for the Function of Two Anti-VEGF Receptor 2 Antibodies

(2011) Matthew C. Franklin et al.   STRUCTURE

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

(2010) R. K. Shrimali et al.   CANCER RESEARCH

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

(2010) Dhanalakshmi Chinnasamy et al.   JOURNAL OF CLINICAL INVESTIGATION

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY